Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316185 · ClinicalTrials.gov registry record · Phase 1
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
A Phase 1 study, sponsored by Eiger BioPharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01316185 is a Phase 1 study that was terminated before completion, run by Eiger BioPharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT01316185, a Phase 1 study, was terminated before completion, sponsored by Eiger BioPharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.
Interventions
- DRUG EBP921
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01316185
The ClinicalTrials.gov registry entry for NCT01316185 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eiger BioPharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EBP921 is the first listed.
NCT01316185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01316185 about?
NCT01316185 is a clinical study titled "Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)". The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.
What is the current status of trial NCT01316185?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01316185?
The interventions under investigation include: EBP921 (DRUG).
Who is sponsoring clinical trial NCT01316185?
This trial is sponsored by Eiger BioPharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.